<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578277</url>
  </required_header>
  <id_info>
    <org_study_id>206294</org_study_id>
    <secondary_id>AI468-063</secondary_id>
    <nct_id>NCT02578277</nct_id>
  </id_info>
  <brief_title>Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates</brief_title>
  <official_title>Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to study the effects of BMS-955176 on the single-dose PK
      parameters of probe substrates caffeine, metoprolol, montelukast, flurbiprofen, omeprazole,
      midazolam, digoxin, and pravastatin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2015</start_date>
  <completion_date type="Actual">December 23, 2015</completion_date>
  <primary_completion_date type="Actual">December 23, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration)</measure>
    <time_frame>Days 1 to 18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-T), area under the concentration-time curve from time zero to the time of the last quantifiable concentration</measure>
    <time_frame>Days 1 to 18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(INF), area under the concentration-time curve from time zero extrapolated to infinite time</measure>
    <time_frame>Days 1 to 18</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Single sequence, 3-period DDI (drug-drug interaction)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single sequence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYP and transporter probe substrates</intervention_name>
    <description>Cocktail of CYP (cytochrome P450) and transporter probe substrates</description>
    <arm_group_label>Single sequence, 3-period DDI (drug-drug interaction)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-955176</intervention_name>
    <description>BMS-955176</description>
    <arm_group_label>Single sequence, 3-period DDI (drug-drug interaction)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-955176 plus CYP and transporter probe substrates</intervention_name>
    <description>BMS-955176 plus the cocktail of CYP and transporter probe substrates</description>
    <arm_group_label>Single sequence, 3-period DDI (drug-drug interaction)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written Informed Consent

          2. Healthy male and female (not of childbearing potential) subjects as determined by
             medical history, surgical history, physical examination, vital signs, ECGs, and
             clinical laboratory determinations

          3. Body mass index (BMI) of 18.0 kg/m2 to 32.0 kg/m2, inclusive, at screening and Day 1.
             BMI = weight (kg)/[height(m)]

          4. Women must have documented proof that they are not of childbearing potential (eg,
             surgically sterile, postmenopausal with a documented follicle-stimulating hormone
             (FSH) &gt; 40 mIU/mL) and should not be breast feeding

          5. Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception for the duration of treatment with BMS-955176 in addition
             to a post-treatment completion period

        Exclusion Criteria:

          1. Any significant acute or chronic medical illness

          2. Use of tobacco, excessive alcohol

          3. Medical history indicative of an increased risk of a cardiac arrhythmia or cardiac
             disease and history of asthma, bronchospasm, sleep apnea, rhabdomyolysis, a bleeding
             disorder, a major depressive disorder within the past 6 months, peptic ulcer or
             significant GI bleed, Raynaud's disease, or any gastrointestinal surgery that could
             impact upon the absorption of study drug

          4. Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG, or clinical laboratory determinations beyond
             what is consistent with the target population

          5. History of allergy to BMS-955176, digoxin (or any member of the digitalis glycosides
             class of drugs), caffeine, metoprolol, montelukast, flurbiprofen, omeprazole,
             midazolam, or pravastatin, or to any related compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-955176</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

